tbuckley/cabot-search huggingface dataset:
Deciphering the Mechanics of Cancer Spheroid Growth in 3D Environments through Microfluidics Driven Mechanical Actuation
Authors: Aereas Aung, Shruti K. Davey, Jomkuan Theprungsirikul, Vardhman Kumar, Shyni Varghese
Journal: Advanced Healthcare Materials (2022)

Abstract Uncontrolled growth of tumor cells is a key contributor to cancer‐associated mortalities. Tumor growth is a biomechanical process whereby the cancer cells displace the surrounding matrix that provides mechanical resistance to the growing cells. The process of tumor growth and remodeling is regulated by material properties of both the cancer cells and their surrounding matrix, yet the mechanical interdependency between the two entities is not well understood. Herein, this work develops a microfluidic platform that precisely positions tumor spheroids within a hydrogel and mechanically probes the growing spheroids and surrounding matrix simultaneously. By using hydrostatic pressure to deform the spheroid‐laden hydrogel along with confocal imaging and finite element (FE) analysis, this work deduces the material properties of the spheroid and the matrix in situ. For spheroids embedded within soft hydrogels, decreases in the Young's modulus of the matrix are detected at discrete locations accompanied by localized tumor growth. Contrastingly, spheroids within stiff hydrogels do not significantly decrease the Young's modulus of the surrounding matrix, despite exhibiting growth. Spheroids in stiff matrices leverage their high bulk modulus to grow and display a uniform volumetric expansion. Collectively, a quantitative platform is established and new insights into tumor growth within a stiff 3D environment are provided.
Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms
Authors: Yanfang Yang, Ke Feng, Liying Yuan, Yuxin Liu, Mengying Zhang, Kaimin Guo, Zequn Yin, Wenjia Wang, Shuiping Zhou, He Sun, Kaijing Yan, Xijun Yan, Xuerui Wang, Yajun Duan, Yunhui Hu, Jihong Han
Journal: Acta Pharmaceutica Sinica B (2022)

Heart failure is the leading cause of death worldwide. Compound Danshen Dripping Pill (CDDP) or CDDP combined with simvastatin has been widely used to treat patients with myocardial infarction and other cardiovascular diseases in China. However, the effect of CDDP on hypercholesterolemia/atherosclerosis-induced heart failure is unknown. We constructed a new model of heart failure induced by hypercholesterolemia/atherosclerosis in apolipoprotein E (ApoE) and LDL receptor (LDLR) dual deficient (ApoE-/-LDLR-/-) mice and investigated the effect of CDDP or CDDP plus a low dose of simvastatin on the heart failure. CDDP or CDDP plus a low dose of simvastatin inhibited heart injury by multiple actions including anti-myocardial dysfunction and anti-fibrosis. Mechanistically, both Wnt and lysine-specific demethylase 4A (KDM4A) pathways were significantly activated in mice with heart injury. Conversely, CDDP or CDDP plus a low dose of simvastatin inhibited Wnt pathway by markedly up-regulating expression of Wnt inhibitors. While the anti-inflammation and anti-oxidative stress by CDDP were achieved by inhibiting KDM4A expression and activity. In addition, CDDP attenuated simvastatin-induced myolysis in skeletal muscle. Taken together, our study suggests that CDDP or CDDP plus a low dose of simvastatin can be an effective therapy to reduce hypercholesterolemia/atherosclerosis-induced heart failure.
Cell-derived nanovesicles from mesenchymal stem cells as extracellular vesicle-mimetics in wound healing
Authors: Yub Raj Neupane, Harish K. Handral, Syed Abdullah Alkaff, Wei Heng Chng, Gopalakrishnan Venkatesan, Chenyuan Huang, Choon Keong Lee, Jiong-Wei Wang, Gopu Sriram, Rhonnie Austria Dienzo, Wen Feng Lu, Yusuf Ali, Bertrand Czarny, Giorgia Pastorin
Journal: Acta Pharmaceutica Sinica B (2022)

Wound healing is a dynamic process that involves a series of molecular and cellular events aimed at replacing devitalized and missing cellular components and/or tissue layers. Recently, extracellular vesicles (EVs), naturally cell-secreted lipid membrane-bound vesicles laden with biological cargos including proteins, lipids, and nucleic acids, have drawn wide attention due to their ability to promote wound healing and tissue regeneration. However, current exploitation of EVs as therapeutic agents is limited by their low isolation yields and tedious isolation processes. To circumvent these challenges, bioinspired cell-derived nanovesicles (CDNs) that mimic EVs were obtained by shearing mesenchymal stem cells (MSCs) through membranes with different pore sizes. Physical characterisations and high-throughput proteomics confirmed that MSC-CDNs mimicked MSC-EVs. Moreover, these MSC-CDNs were efficiently uptaken by human dermal fibroblasts and demonstrated a dose-dependent activation of MAPK signalling pathway, resulting in enhancement of cell proliferation, cell migration, secretion of growth factors and extracellular matrix proteins, which all promoted tissue regeneration. Of note, MSC-CDNs enhanced angiogenesis in human dermal microvascular endothelial cells in a 3D PEG-fibrin scaffold and animal model, accelerating wound healing in vitro and in vivo. These findings suggest that MSC-CDNs could replace both whole cells and EVs in promoting wound healing and tissue regeneration.
Patient-Reported Outcomes of COVID-19 Vaccine Breakthrough Infection–Associated Changes in Glucose Control in Subjects With Type 1 Diabetes (PRO-VACS 2 Study)
Authors: Ilaria Dicembrini, Daniele Scoccimarro, Gloria Giovanna Del Vescovo, Christian Marinelli, Elena Zago, Chiara Delli Poggi, Laura Pala, Edoardo Mannucci
Journal: Diabetes Care (2022)
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
Authors: Ido Yofe, Tomer Landsberger, Adam Yalin, Isabelle Solomon, Cristobal Costoya, Dafne Franz Demane, Mansi Shah, Eyal David, Chamutal Borenstein, Oren Barboy, Ignacio Matos, Karl S. Peggs, Sergio A. Quezada, Ido Amit
Journal: Nature Cancer (2022)
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric <i>BRAF</i> V600–Mutant Low-Grade Glioma
Authors: Eric Bouffet, Birgit Geoerger, Christopher Moertel, James A. Whitlock, Isabelle Aerts, Darren Hargrave, Lisa Osterloh, Eugene Tan, Jeea Choi, Mark Russo, Elizabeth Fox
Journal: Journal of Clinical Oncology (2022)

PURPOSE BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). Here, we describe a phase I/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as well as efficacy and safety in a disease-specific cohort with BRAF V600–mutant LGG; other cohorts will be reported elsewhere. METHODS This is a four-part, phase I/II study (ClinicalTrials.gov identifier: NCT02124772 ) in patients age &lt; 18 years with relapsed/refractory malignancies: trametinib monotherapy dose finding (part A) and disease-specific expansion (part B), and dabrafenib + trametinib dose finding (part C) and disease-specific expansion (part D). The primary objective assessed in all patients in parts A and C was to determine pediatric dosing on the basis of steady-state pharmacokinetics. Disease-specific efficacy and safety (across parts A-D) were secondary objectives. RESULTS Overall, 139 patients received trametinib (n = 91) or dabrafenib + trametinib (n = 48). Trametinib dose-limiting toxicities in &gt; 1 patient (part A) included mucosal inflammation (n = 3) and hyponatremia (n = 2). There were no dose-limiting toxicities with combination therapy (part C). The recommended phase II dose of trametinib, with or without dabrafenib, was 0.032 mg/kg once daily for patients age &lt; 6 years and 0.025 mg/kg once daily for patients age ≥ 6 years; dabrafenib dosing in the combination was as previously identified for monotherapy. In 49 patients with BRAF V600–mutant glioma (LGG, n = 47) across all four study parts, independently assessed objective response rates were 15% (95% CI, 1.9 to 45.4) for monotherapy (n = 13) and 25% (95% CI, 12.1 to 42.2) for combination (n = 36). Adverse event–related treatment discontinuations were more common with monotherapy (54% v 22%). CONCLUSION The trial design provided efficient evaluation of pediatric dosing, safety, and efficacy of single-agent and combination targeted therapy. Age-based and weight-based dosing of trametinib with or without dabrafenib achieved target concentrations with manageable safety and demonstrated clinical efficacy and tolerability in BRAF V600–mutant LGG.
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
Authors: Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Salomon Manier, Laure Buisson, Sabrina Mahéo, Laura Do Souto Ferreira, Luka Pavageau, Cyrille Hulin, Jean-Pierre Marolleau, Laurent Voillat, Karim Belhadj, Marion Divoux, Borhane Slama, Sabine Brechignac, Margaret Macro, Anne-Marie Stoppa, Laurence Sanhes, Frédérique Orsini-Piocelle, Jean Fontan, Marie-Lorraine Chretien, Hélène Demarquette, Mohamad Mohty, Hervé Avet-Loiseau, Jill Corre
Journal: Blood (2022)
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Authors: Pierre-Yves Dumas, Emmanuel Raffoux, Emilie Bérard, Sarah Bertoli, Marie-Anne Hospital, Maël Heiblig, Yohann Desbrosses, Caroline Bonmati, Cécile Pautas, Juliette Lambert, Corentin Orvain, Anne Banos, Florence Pasquier, Pierre Peterlin, Tony Marchand, Madalina Uzunov, Jamilé Frayfer, Pascal Turlure, Thomas Cluzeau, Eric Jourdan, Chantal Himberlin, Emmanuelle Tavernier, Alban Villate, Stephanie Haiat, Marie-Lorraine Chretien, Martin Carre, Sylvain Chantepie, Ioana Vaida, Mathieu Wemeau, Safia Chebrek, Gaelle Guillerm, Romain Guièze, Houria Debarri, Eve Gehlkopf, Kamel Laribi, Ambroise Marcais, Alberto Santagostino, Marie-Christine Béné, Ariane Mineur, Arnaud Pigneux, Hervé Dombret, Christian Récher
Journal: Leukemia (2022)
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts
Authors: Deyi Zhang, Hailey M. Harris, Jonathan Chen, Jen Judy, Gabriella James, Aileen Kelly, Joel McIntosh, Austin Tenn-McClellan, Eileen Ambing, Ying Siow Tan, Hao Lu, Stefan Gajewski, Matthew C. Clifton, Stephanie Yung, Daniel W. Robbins, Mehdi Pirooznia, Sigrid S. Skånland, Erika Gaglione, Maissa Mhibik, Chingiz Underbayev, Inhye E. Ahn, Clare Sun, Sarah E. M. Herman, Mark Noviski, Adrian Wiestner
Journal: Blood (2022)
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa
Authors: Peter Olupot-Olupot, George Tomlinson, Thomas N. Williams, Léon Tshilolo, Brígida Santos, Luke R. Smart, Kathryn McElhinney, Thad A. Howard, Banu Aygun, Susan E. Stuber, Adam Lane, Teresa S. Latham, Russell E. Ware
Journal: Blood (2022)
Bronchial epithelial cell transcriptome shows endotype heterogeneity of asthma in patients with NSAID-exacerbated respiratory disease
Authors: Bogdan Jakiela, Jerzy Soja, Krzysztof Sladek, Marek Przybyszowski, Hanna Plutecka, Anna Gielicz, Sabina Licholai, Alar Aab, Ana Rebane, Grazyna Bochenek
Journal: Journal of Allergy and Clinical Immunology (2022)
Advisory Board and Contents
Authors: Yubao Cheng, Siyuan Wang, Tan Wu, Hao Huang, Xin Wang, Ellie Maas, Brigid Betz-Stablein, Lauren Aoude, H Soyer, Aideen Mcinerney-Leo, Martin Fischer, Steve Hoffmann, Rohini Nair, Emese Pataki, Jeffrey Gerst, Huw Jones, Philippe Wilson, Tien-Hung Lan, Lian He, Yun Huang, Yubin Zhou, Bryan Harada, Danielle Loughlin, Yvonne Philippo, Patrick Scheffmann, Asifa Akhtar, Erik Andersen, Kirsten Bomblies, Martha Bulyk, Ling Chen, Andy Clark, Sue Clark, Caixia Gao, Sanjeev Galande, Susan Gasser, David Goldstein, Leonard Guarente, Yoshihide Hayashizaki, Steven Henikoff, Chris Hittinger, Laurence Hurst, Bat-Sheva Kerem, Aldons Lusis, Angela Nieto, Chris Ponting, Claudio Scazzocchio, Bob Schmitz, Nicole Soranzo, Trisha Wittkopp, Joanna Wysocka, Catherine Kelly, Anita Szabo, Nikolas Pontikos, Gavin Arno, Peter Robinson, Jules Jacobsen, Damian Smedley, Valentina Cipriani, Merlin Crossley, Georgios Christakopoulos, Mitchell Weiss
Journal: Trends in Genetics (2022)
Janus Micro/Nanorobots in Biomedical Applications
Authors: Haiyang Su, Shunxiang Li, Guang‐Zhong Yang, Kun Qian
Journal: Advanced Healthcare Materials (2022)

Abstract Janus particles possess two or more distinct domains that are anisotropic in composition or surface features. They integrate different or even incompatible properties within a single particle, making them possible to perform diverse functions and multiple tasks simultaneously. Advances in micro/nanorobots demonstrate that they can effectively convert diverse energy sources into movement and reach target locations with precision. Integration of Janus structure with micro/nanobots is emerging as a promising tool for biomedical applications. In this review, the fabrication and energy sources of Janus micro/nanorobots are briefly introduced. After that, the recent progress of Janus micro/nanorobots for biomedicine, with a special focus on their applications for cargo delivery, bioimaging, biosensing, surgery, and therapy are presented and discussed. The application of Janus micro/nanorobots in biomedicine still faces serious challenges from fabrication, engines, biocompatibility, and biodegradation for their widespread in clinical situations. Nevertheless, a few emerging materials and approaches offer potential solutions to these problems.
Dual “Unlocking” Strategy to Overcome Inefficient Nanomedicine Delivery and Tumor Hypoxia for Enhanced Photodynamic‐Immunotherapy
Authors: Xianglong Li, Cong Jiang, Xinlin Jia, Yuanyuan Cao, Yuanqing Mao, Ji‐Na Hao, Yang Yang, Peng Zhang, Yongsheng Li
Journal: Advanced Healthcare Materials (2022)

Lacking blood vessels is one of the main characteristics of most solid tumors due to their rapid and unrestricted growth, which thus causes the inefficient delivery efficiency of nanomedicine and tumor hypoxia. Herein, a dual "unlocking" strategy to overcome these obstacles is proposed by combining engineered hybrid nanoparticles (named ZnPc@FOM-Pt) with dexamethasone (DXM). It is verified that pretreatment of tumors with DXM can increase intratumorally micro-vessel density (delivery "unlocking") to enhance the tumor delivery efficiency of ZnPc@FOM-Pt and decrease HIF-1α expression. Correspondingly, more Pt can catalyze tumor-overexpressed H2 O2 to produce oxygen to further cause hypoxia "unlocking," ultimately achieving boosted ZnPc-based photodynamic therapy in vivo (tumor inhibition rate: 99.1%). Moreover, the immunosuppressive tumor microenvironment is efficiently reversed and the therapeutic effect of anti-PD-L1-based immunotherapy is promoted by this newly designed nanomedicine. This dual "unlocking" strategy provides an innovative paradigm on simultaneously enhancing nanomedicine delivery efficacy and hypoxia relief for tumor therapy.
Tumor Cell‐Responsive Photodynamic Immunoagent for Immunogenicity‐Enhanced Orthotopic and Remote Tumor Therapy
Authors: Yingchao Chen, Tao Xiong, Xueze Zhao, Jianjun Du, Wen Sun, Jiangli Fan, Xiaojun Peng
Journal: Advanced Healthcare Materials (2022)

Abstract Combining photodynamic therapy (PDT) and immune checkpoint blockades is an efficient method to maximize immunotherapeutic outcome by boosting tumor immunogenicity and modulating the immunosuppressive tumor microenvironment. However, the always‐on bioactivity of photosensitizers or immune checkpoint inhibitors leads to uncontrollable side effects, limiting the in vivo therapeutic efficacy of treatments. An activatable strategy is of great importance for improving the selectivity during cancer therapy. In this study, a photodynamic immunomodulator, ICy‐NLG, is developed by conjugating the photosensitizer ICy‐NH2 with the indoleamine 2,3‐dioxygenase 1 inhibitor NLG919 through a glutathione (GSH)‐cleavable linker to achieve activatable photodynamic immunotherapy. The conjugation considerably suppresses both the PDT effect and the activity of the inhibitor. After ICy‐NLG is activated by high levels of GSH in tumor cells, the PDT effect is restored and leads to immunogenic tumor cell death. The released tumor‐associated antigens in conjunction with the activated immune checkpoint inhibitor induce a synergistic antitumor immune response, resulting in the growth inhibition of primary and distant tumors and the prevention of lung metastasis in mouse xenograft models.
Lipoplex‐Functionalized Thin‐Film Surface Coating Based on Extracellular Matrix Components as Local Gene Delivery System to Control Osteogenic Stem Cell Differentiation
Authors: Catharina Husteden, Yazmin A. Brito Barrera, Sophia Tegtmeyer, João Borges, Julia Giselbrecht, Matthias Menzel, Andreas Langner, João F. Mano, Christian E. H. Schmelzer, Christian Wölk, Thomas Groth
Journal: Advanced Healthcare Materials (2022)

Abstract A gene‐activated surface coating is presented as a strategy to design smart biomaterials for bone tissue engineering. The thin‐film coating is based on polyelectrolyte multilayers composed of collagen I and chondroitin sulfate, two main biopolymers of the bone extracellular matrix, which are fabricated by layer‐by‐layer assembly. For further functionalization, DNA/lipid‐nanoparticles (lipoplexes) are incorporated into the multilayers. The polyelectrolyte multilayer fabrication and lipoplex deposition are analyzed by surface sensitive analytical methods that demonstrate successful thin‐film formation, fibrillar structuring of collagen, and homogenous embedding of lipoplexes. Culture of mesenchymal stem cells on the lipoplex functionalized multilayer results in excellent attachment and growth of them, and also, their ability to take up cargo like fluorescence‐labelled DNA from lipoplexes. The functionalization of the multilayer with lipoplexes encapsulating DNA encoding for transient expression of bone morphogenetic protein 2 induces osteogenic differentiation of mesenchymal stem cells, which is shown by mRNA quantification for osteogenic genes and histochemical staining. In summary, the novel gene‐functionalized and extracellular matrix mimicking multilayer composed of collagen I, chondroitin sulfate, and lipoplexes, represents a smart surface functionalization that holds great promise for tissue engineering constructs and implant coatings to promote regeneration of bone and other tissues.
LBL Noninvasively Peelable Biointerfacial Adhesives for Cutaneo‐Inspired pH/Tactility Artificial Receptors
Authors: Renqiang Yuan, Ning Yang, Weikun Li, Zonghao Liu, Fang Feng, Qianli Zhang, Liqin Ge
Journal: Advanced Healthcare Materials (2022)

Besides barrier functions, skin possesses multiple sentiences to external stimuli (e.g., temperature, force, and humidity) for human-outside interaction. Thus, skincare should be taken very seriously, especially by patients with sensory disorders. However, currently available skin-mimicking devices are always limited by so much insufficient response functions and nontunable interface behaviors so as not to realize precise health monitoring and self-defense against injury. Herein, a bioinspired cutaneous receptor-perceptual system (CRPS) patch is presented, integrating hybrid pH indicators and triboelectric nanogenerators into biointerface film-adhesives that are fabricated through facile layer-by-layer (LBL) self-assembly of amide and Schiff-base linkages between alginate grafted with N-hydroxysuccinimide ester (AN), tannic acid (TA), and polyethylenimine (PEI). This CRPS patch is adhered robustly to the soft-curved skin surface without failure via "molecular suturing," and amino acid enables its benign peel-on-demand from tissue interfaces. Postdamage self-healing brings it without surgical reoperation, avoiding extra cost, pain, as well as infection risks. Significantly, CRPS patches as artificial chemo/mechanoreceptors can remotely visualize skin physiological status by pH-induced chromism using smartphones and prevent skin contact injury by tactility-driven self-powered electrical signals. Overall, the LBL-based strategy to create controllably biointerface-adhesive CRPS patches will usher in a new era of the mobihealth care platform supporting smart diagnosis and self-protection.
Self-cleaning wearable masks for respiratory infectious pathogen inactivation by type I and type II AIE photosensitizer
Authors: Jingxuan Sun, Yujie Bai, Eric Y. Yu, Guanyu Ding, Haili Zhang, Ming Duan, Pei Huang, Mengyao Zhang, Hongli Jin, Ryan TK. Kwok, Yuanyuan Li, Guo-Gang Shan, Ben Zhong Tang, Hualei Wang
Journal: Biomaterials (2022)
Surveillance of arthropod-borne viruses in Benin, West Africa 2020–2021: detection of dengue virus 3 in Aedes aegypti (Diptera: Culicidae)
Authors: Carine Tchibozo, Gildas Hounkanrin, Anges Yadouleton, Alexandra Bialonski, Eric Agboli, Renke Lühken, Jonas Schmidt-Chanasit, Hanna Jöst
Journal: Military Medical Research (2022)
A double-edged sword: ROS related therapies in the treatment of psoriasis
Authors: Jingyi Hu, Qiong Bian, Xiaolu Ma, Yihua Xu, Jianqing Gao
Journal: Asian Journal of Pharmaceutical Sciences (2022)

In the onset and progression of psoriasis, redox imbalance is a vital factor. It's widely accepted that too much reactive oxygen species (ROS) always make psoriasis worse. Recent research, however, has shown that the accumulation of ROS is not entirely detrimental, as it helps reduce psoriasis lesions by inhibiting epidermal proliferation and keratinocyte death. As a result, ROS appears to have two opposing effects on the treatment of psoriasis. In this review, the current ROS-related therapies for psoriasis, including basic and clinical research, are presented. Additionally, the design and therapeutic benefits of various drug delivery systems and therapeutic approaches are examined, and a potential balance between anti-oxidative stress and ROS accumulation is also trying to be investigated.
Quantum Healthy Longevity for healthy people, planet, and growth
Authors: Tina Woods, Nic Palmarini, Lynne Corner, Nir Barzilai, Lord James Bethell, Lynne S Cox, Harris Eyre, Luigi Ferrucci, Linda Fried, David Furman, Brian Kennedy, Andrew Roddam, Andrew Scott, Richard C Siow
Journal: The Lancet Healthy Longevity (2022)